Validation of the 2021 EAN/PNS diagnostic criteria for chronic inflammatory demyelinating polyneuropathy
Open Access
- 23 September 2022
- journal article
- editorial
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 93 (12), 1237-1238
- https://doi.org/10.1136/jnnp-2022-329916
Abstract
Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common immune-mediated neuropathy.1 Because of the lack of disease-specific diagnostic biomarkers, the diagnosis depends on combination of clinical, electrodiagnostic, and laboratory/neuroimaging findings, as well as exclusion criteria; and in clinical practice, misdiagnosis is not uncommon.Funding Information
- the Health and Labour Sciences Research Grant on Intractable Diseases (Neuroimmunological Diseases) from the Ministry of Health, Labour and Welfare of Japan (20FC1030)
This publication has 5 references indexed in Scilit:
- Application of the 2021 EAN/PNS criteria for chronic inflammatory demyelinating polyneuropathyJournal of Neurology, Neurosurgery & Psychiatry, 2022
- Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathyJournal of Neurology, Neurosurgery & Psychiatry, 2022
- European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revisionJournal of the Peripheral Nervous System, 2021
- Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatmentJournal of Neurology, Neurosurgery & Psychiatry, 2019
- Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathyJournal of Neurology, Neurosurgery & Psychiatry, 2014